Implantica advances in Sweden with its medical device RefluxStop™
Implantica AG (publ) today announces that RefluxStop™ will start selling in Sweden with reimbursement by public healthcare.
Implantica will now focus on scaling up its sales force in Scandinavia as it introduces RefluxStop™ to the leading anti-reflux surgeons and centers in Sweden, which will be a second home market due to the company’s significant ties to Sweden and its large Scandinavian investor base. Surgical training will commence initially via webinar and will include representatives from Germany and Switzerland.
“We are very pleased to be able to sell RefluxStop™ on a reimbursed basis to the Swedish market,” said Peter Forsell, CEO of Implantica. “At this stage we will mainly focus on the publicly funded hospitals, and we will extend our registry study to Scandinavia in order to collect data for RefluxStop™.”
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, info@fnca.se
The information was sent for publication, through the agency of the contact person set out above, on March 8, 2021 at 08:00 a.m. CET.
About Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.